Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes.

被引：3
|
作者：
Vaidvanathan, S [1 ]
Zhao, C [1 ]
Yeh, C [1 ]
Dieterich, H [1 ]
机构：
[1] Novartis Pharma AG, Novartis Pharmaceut, E Hanover, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 79卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2005.12.042
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P12 / P12
页数：1
相关论文
共 50 条
  • [31] Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension
    Toshio Kushiro
    Hiroshige Itakura
    Yoshihisa Abo
    Hiromi Gotou
    Shinji Terao
    Deborah L Keefe
    Hypertension Research, 2009, 32 : 169 - 175
  • [32] Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type diabetes.
    He, YL
    Balch, A
    Campestrini, J
    Rivere, GJ
    Serra, D
    Prasad, P
    Ligueros-Saylan, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P56 - P56
  • [33] Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes
    Kilo, C.
    Taylor, A.
    Tschoepe, D.
    Ibram, G.
    Fang, H.
    Prescott, M. F.
    EUROPEAN HEART JOURNAL, 2006, 27 : 118 - 119
  • [34] Effect of direct renin inhibitor aliskiren on circulating endothelial progenitor cells number in patients with type 2 diabetes mellitus and arterial hypertension
    Mazioti, M. C.
    Markakis, K. P.
    Raptis, A. E.
    Maratou, E.
    Ikonomidis, I.
    Vlahakos, D. V.
    Tsirogianni, A.
    Raptis, S. A.
    Dimitriadis, G. D.
    DIABETOLOGIA, 2013, 56 : S485 - S485
  • [35] Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
    Vaidyanathan, S
    Jermany, J
    Yeh, CM
    Bizot, MN
    Camisasca, RP
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 75A - 76A
  • [36] Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
    Vaidyanathan, Sujata
    Jermany, Joanne
    Yeh, ChingMing
    Bizot, Marie-Noelle
    Camisasca, Riccardo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 690 - 698
  • [37] Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P-Glycoprotein in the Disposition of Aliskiren
    Vaidyanathan, Sujata
    Camenisch, Gian
    Schuetz, Helmut
    Reynolds, Christine
    Yeh, Ching-Ming
    Bizot, Marie-Noelle
    Dieterich, Hans Armin
    Howard, Dan
    Dole, William R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (11): : 1323 - 1338
  • [38] Nephropathy in patients with type 2 diabetes.
    Remuzzi, G
    Schieppati, A
    Ruggenenti, P
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15): : 1145 - 1151
  • [39] Evaluation of the direct renin inhibitor, aliskiren, in patients on hemodialysis
    Iturralde Iriso, Jesus
    Ocharan Corcuera, Julen
    Mediavilla Tris, Gregorio
    Rodriguez Fernandez, Alfonso
    Ruiz De Gauna, Ramon
    Jimeno, Isabel
    Aurrekoetxea, Begona
    Chena, Alejandro
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 137 : S32 - S32
  • [40] PHARMACOECONOMICS OF DIRECT RENIN INGIBITOR ALISKIREN IN HYPERTENSION TREATMENT OF PATIENTS WITH TYPE-2 DIABETES AND NEPHROPATHY
    Rudakova, A., V
    VALUE IN HEALTH, 2009, 12 (07) : A331 - A331
12345